Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CPL 500036

Next Previous
Drug Profile

CPL 500036

Alternative Names: CPL'36; CPL-500-036-02; CPL500036; CZ20; PG203; SUB193569

Latest Information Update: 13 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Celon Pharma
  • Developer Celon Pharma; The National Centre for Research and Development
  • Class 2 ring heterocyclic compounds; Antipsychotics; Azoles; Imidazoles; Pyrazines; Pyrimidines; Small molecules; Triazoles
  • Mechanism of Action Phosphodiesterase 10A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Drug-induced dyskinesia; Schizophrenia
  • No development reported Huntington's disease

Most Recent Events

  • 04 Mar 2025 Efficacy and adverse events data from phase II trials in Drug induced dyskinesia released by Celon Pharma
  • 27 Jan 2025 Celon Pharma completes phase-II clinical trials in Drug-induced dyskinesia in Poland and Ukraine (PO) (NCT05297201)
  • 09 Jul 2024 Celon Pharma plans a discussion with regulatory agencies to advance CPL 500036 towards registrational trials and global marketing approvals

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top